| Literature DB >> 29599767 |
Julio Villena1,2,3, Hisashi Aso4,5, Victor P M G Rutten6, Hideki Takahashi7,8, Willem van Eden6, Haruki Kitazawa3,5.
Abstract
The scientific community has reported several cases of microbes that exhibit elevated rates of antibiotic resistance in different regions of the planet. Due to this emergence of antimicrobial resistant microorganisms, the use of antibiotics as promoters of livestock animals' growth is being banned in most countries around the world. One of the challenges of agricultural immunology therefore is to find alternatives by modulating the immune system of animals in drug-independent safe food production systems. In this regard, in an effort to supplant antibiotics from bovine feeds, several alternatives were proposed including the use of immunomodulatory probiotics (immunobiotics). The purpose of this review is to provide an update of the status of the modulation of intestinal antiviral innate immunity of the bovine host by immunobiotics, and the beneficial impact of immunobiotics on viral infections, focused on intestinal epithelial cells (IECs). The results of our group, which demonstrate the capacity of immunobiotic strains to beneficially modulate Toll-like receptor 3-triggered immune responses in bovine IECs and improve the resistance to viral infections, are highlighted. This review provides comprehensive information on the innate immune response of bovine IECs against virus, which can be further investigated for the development of strategies aimed to improve defenses in the bovine host.Entities:
Keywords: agricultural immunology; antiviral immunity; beneficial microbes; bovine rotavirus; immunobiotics; inflammation; toll-like receptor 3 pathway
Mesh:
Substances:
Year: 2018 PMID: 29599767 PMCID: PMC5863502 DOI: 10.3389/fimmu.2018.00326
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Probiotics for the bovine host.
| Strain | Viability | Route | Host | Effects | Reference |
|---|---|---|---|---|---|
| Viable | Oral | Holstein calves | Increase in body weight gain. Improvement in fecal scores | ( | |
| Viable | Oral | Holstein calves | Increase in body weight gain. Improvement in fecal scores | ( | |
| Viable | Oral | Holstein calves | No effect on body weight gain was observed. Reduction of diarrhea | ( | |
| Viable | Oral | Holstein calves | Improvement in daily live weight gain and feed efficiency ratio. Reduction of diarrhea | ( | |
| Viable | Oral | Holstein calves | The probiotic strain survived the gastrointestinal transit. No beneficial effect was recorded | ( | |
| Viable | Oral | Holstein bull calves | Treated animals consumed more grain, had increased weight gain, and increased plasma glucose concentrations. Days with diarrhea were reduced | ( | |
| Viable | Oral | buffalo calve (1 day to 31 weeks) | Weight gain was improved and feed: gain ratio was reduced | ( | |
| Multispecies probiotic preparation: | Viable | Oral | Male Holstein-Friesian calves | Probiotics enhanced growth rate and average daily gain and feed efficiency were significantly improved. Modest effect on diarrhea | ( |
| Calf-specific multistrain probiotic preparation (six lactobacilli strains) | Viable | Oral | Male Holstein-Friesian calves | Probiotics enhanced growth rate and average daily gain and feed efficiency were significantly improved. Treatment reduced the incidence of diarrhea and the fecal counts of coliforms | ( |
| Viable | Oral | Holstein dairy calves | Increase the milk production | ( | |
| Lactobacillus | Viable | Oral | Holstein calves | Significant reduction of diarrhea but no effect on mastitis | ( |
| Viable | Oral | Male Holstein calves | Increased average daily gain and feed efficiency. No difference in serum IgE, IgA, and IgM, whereas serum IgG and IFN-γ were higher in probiotic-treated than in the controls. | ( | |
| Viable | Oral | Holstein bull calves | Increased the numbers of CD282+ monocytes, CD3+ T cells and CD4+, CD8+, and WC1+ γδ T cell in blood. Increment of production of IL-6, INF-γ, and TNF-α were also observed | ( | |
| Viable | Oral | Preweaned dairy Holstein heifer calves | Decreased the incidence of severe diarrhea and related mortality rate, while increasing weight gain | ( | |
| Viable | Oral | Male Holstein calves | No significant differences were observed in dry matter intake or average daily gain, but the feed conversation ratio was improved. Treatment improved mitogen-induced lymphocyte proliferation | ( | |
| Kefir | Viable | Oral | Female Holstein calves calves | Kefir intake improved fecal scores and reduced days with diarrhea during the first 2 weeks of life. No effect on weight gain | ( |
| Milk fortified with symbiotic complex containing prebiotics (mannan-oligossacharides) and probiotics ( | Viable | Oral | Female Holstein heifer calves | Symbiotic did not affect weight gain or feed efficiency of calves but it improved fecal scores | ( |
Figure 1Antiviral Innate immune response against rotavirus in bovine intestinal epithelial (BIE) cells. Rotavirus double-stranded genomic RNA activates toll-like receptor 3 (TLR3), retinoic acid inducible gene-I (RIG-I), and melanoma differentiation-associated gene-5 (MDA-5), which are pattern recognition receptors (PRRs) expressed in BIE cells. Cellular signaling cascades are activated and converge at the level of interferon (IFN) regulatory factor-3 (IRF3) that upregulate the expression of type I (IFN-α, IFN-β) and type III (IFNλ1, IFNλ2/3) IFN, which in turn induces the synthesis of IFN-stimulated genes with antiviral activities including: myxovirus resistance 1 IFN-inducible protein (Mx1), MxA, ribonuclease L (RNaseL), 2′-5′-oligoadenylate synthetase (OAS), and protein kinase R (PKR). Antiviral PRRs also activate nuclear factor κB (NF-κB) pathway and induce the secretion of proinflammatory cytokines and chemokines including: interleukin 6 (IL-6), IL-8, monocyte chemotactic protein 1 (MCP-1/CCL2), and IFN gamma-induced protein 10 (IP-10/CXCL10).
Figure 2Beneficial effects of immunobiotics on the antiviral innate immune response against rotavirus in bovine intestinal epithelial (BIE) cells. Rotavirus doublestranded genomic RNA activates toll-like receptor 3 (TLR3), retinoic acid inducible gene-I (RIG-I), and melanoma differentiation-associated gene-5 (MDA-5), which are pattern recognition receptors (PRRs) expressed in IECs. Cellular signaling cascades mediated by interferon (IFN) regulatory factor-3 (IRF3) upregulate the expression of type I (IFN-α, IFN-β), and type III (IFNλ1, IFNλ2/3) IFN, which in turn induces the synthesis of IFN-stimulated genes with antiviral activities including: myxovirus resistance 1 IFN-inducible protein (Mx1), MxA, ribonuclease L (RNaseL), 2′-5′-oligoadenylate synthetase (OAS), and protein kinase R (PKR). Antiviral PRRs also activate nuclear factor κB (NF-κB) pathway and induce the secretion of proinflammatory cytokines and chemokines including: interleukin 6 (IL-6), IL-8, monocyte chemotactic protein 1 (MCP-1/CCL2), and IFN gamma-induced protein 10 (IP-10/CXCL10). Preventive treatment of BIE cells with immunobiotics increase the activation of IRF3, improve the production of the antiviral factors and differentially regulate the expression of inflammatory mediators.